Foreword Free

Since the addition of temozolomide as oral chemotherapy to the standard treatment of patients with glioblastoma, nearly 20 years have elapsed without a further major breakthrough in the treatment of patients with glioma.¹ Anti-angiogenic agents, immunotherapy, and targeted treatments proved successful in (subsets of) non–central nervous system cancers, but not for patients with diffuse glioma.^2–8 Therefore, the recently demonstrated effective targeted treatment with the mutant isocitrate dehydrogenase (IDH) inhibitor vorasidenib is a long-awaited game-changer for patients with IDH-mutant low-grade glioma.⁹ The key trial results open up to further study initiatives to define the future indications of use in IDH-mutant glioma. The US Food and Drug Administration has already approved vorasidenib for IDH-mutant low-grade glioma. In parallel, healthcare professionals and their patients look for guidance on the use of this new treatment in clinical practice now.

The initiative for this supplement for the practicing healthcare professional arose during the yearly Society for Neuro-Oncology and European Association of Neuro-Oncology conferences in late 2023, in discussion with and endorsed by the leadership of both societies. The two Guest Editors, Katherine Peters and Marjolein Geurts and the team of authors for the supplement worked with enthusiasm and speed, fully supported by the editorial management team and Oxford University Press. Last but not least, the Servier Group provided the financial means for this supplement.

Supplement sponsorship

This article appears as part of the supplement “Practical Management of Patients With IDH-Mutant Glioma,” sponsored by Servier.

References